[ad_1]
SHANGHAI, June 25, 2022 /PRNewswire/ — On June 15, 2022Dragon Boat announced that its IND application of the innovative anti-CLDN 18.2/CD47 bi-specific antibody (bsAb) injection (R&D code: BC007) was officially accepted by National Medical Products Administration (NMPA) under the acceptance number CXSL2200267. This drug is the first domestic clinical filing of the CLDN 18.2/ CD47 bsAb, which is intended for the treatment of late stage solid tumors.
|
Acceptance |
Drug |
Drug Type |
Application Type |
Registration |
Company |
Date |
|
CXSL2200267 |
BC007 |
Therapeutic |
Pharmaceutics |
1 |
Full story available on Benzinga.com
[ad_2]
Source link
